1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975; 50:29–40.
2. Batsakis JG. Pathology consultation. Plasma cell tumors of the head and neck. Ann Otol Rhinol Laryngol. 1983; 92:311–313.
3. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995; 45:8–30.
Article
4. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992; 69:1513–1517.
Article
5. Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992; 6:347–358.
Article
6. Lee SH, Huang JJ, Pan WL, Chan CP. Gingival mass as the primary manifestation of multiple myeloma: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 82:75–79.
7. Epstein JB, Voss NJ, Stevenson-Moore P. Maxillofacial manifestations of multiple myeloma. An unusual case and review of the literature. Oral Surg Oral Med Oral Pathol. 1984; 57:267–271.
8. Lambertenghi-Deliliers G, Bruno E, Cortelezzi A, Fumagalli L, Morosini A. Incidence of jaw lesions in 193 patients with multiple myeloma. Oral Surg Oral Med Oral Pathol. 1988; 65:533–537.
9. Mondello P, Pitini V, Arrigo C, Mondello S, Mian M, Altavilla G. Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. Springerplus. 2014; 3:123.
Article
10. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012; 104:1059–1067.
Article
11. Lee SH, Chan RC, Chang SS, Tan YL, Chang KH, Lee MC, et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Support Care Cancer. 2014; 22:553–560.
Article
12. Utreja A, Almas K, Javed F. Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update. Odontostomatol Trop. 2013; 36:38–46.
13. Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol. 1994; 25:308–318.
Article
14. Bladé J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med. 1996; 156:1463–1468.
15. Matsumura S, Kishino M, Ishida T, Furukawa S. Radiographic findings for solitary plasmacytoma of the bone in the anterior wall of the maxillary sinus: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89:651–657.
Article
16. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol. 1998; 103:902–910.
Article
17. Mozaffari E, Mupparapu M, Otis L. Undiagnosed multiple myeloma causing extensive dental bleeding: report of a case and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94:448–453.
Article
18. Yaegaki K, Kameyama T, Takenaka M, Kimura T, Sujaku C, Tanimura A. Myelomatosis (IgD, lambda) discovered by oral manifestation. Int J Oral Surg. 1985; 14:381–384.
19. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24:945–952.
Article
20. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65:369–376.
21. Assael LA. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg. 2004; 62:125–126.
Article